Shared decision-making practices and patient values in pharmacist outpatient care for rheumatic disease: A multiple correspondence analysis.

Abstract

Purpose: To investigate the value-to-value relationships, relationship between values and patient background, continuation rate of treatment after shared decision-making (SDM), and disease status in order to clarify the values involved in drug therapy decisions for patients with rheumatic disease. Methods: We investigated patient values (efficacy of drug therapy [effectiveness], safety, economics, daily life, and other) and the continuance rate and disease status of treatment after 6 months in 94 patients with rheumatic disease aged ≥18 years who made decisions with pharmacists and physicians in the pharmacy outpatient clinic between September 2019 and April 2021. Multiple correspondence and K-means cluster analyses were performed to show the relationship between values and basic patient information. Results: Among the selected patients, 87% and 47% selected effectiveness for multiple selections and single selection, respectively. Effectiveness was at the center of the graph; three clusters containing other values were placed around it. History of allergy or side effects caused by biologics or Janus kinase inhibitors were in the safety cluster. The non-usage history of biologics or Janus kinase inhibitors was in the economic cluster. Conclusion: Effectiveness was the most important factor for patients with rheumatic disease; the values that patients consider important may shift from effectiveness to other values based on each patient's subjective experience with the treatment and/or the stage of life in which they were treated. It is important to positively link patient values and information about the treatment plan in shared decision-making while establishing rapport with the patient.

• Authors: Ikkou Hirata, Shunsuke Hanaoka, Ryo Rokutanda, Ryohkan Funakoshi, Hiroyuki Hayashi
• Journal: Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques (J Pharm Pharm Sci) Vol. 26 Pg. 11135 ( 2023) ISSN: 1482-1826 [Electronic] Switzerland
• PMID: 36942300 (Publication Type: Journal Article)
• Copyright: Copyright © 2023 Hirata, Hanaoka, Rokutanda, Funakoshi and Hayashi.

Chemical References

• Janus Kinase Inhibitors

Topics

• Humans
• Adolescent
• Adult
• Decision Making
• Pharmacists
• Janus Kinase Inhibitors
• Ambulatory Care
• Hypersensitivity